[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100412442":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":32,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PHA SA CO",null,"patients having a severe infection treated by injection of phages, with or without surgery",[13],"Other: Adverse event after injection of phages",{"label":15,"type":10,"description":16,"interventionNames":17},"PhageRESPONSE","ancillary study : Establish a biobanking of serums, plasmas and PBMC (Peripheral Blood Mononuclear Cells) of patients who have been treated with phage therapy for a bacterial infection.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Adverse event after injection of phages","rate and description of adverse event after injection of phages",[9,15],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Johanna Boulant, CRA","CONTACT","04 26 73 29 38","johanna.boulant@chu-lyon.fr",{"name":30,"role":26,"phone":27,"phoneExt":10,"email":31},"Tristan Ferry, Md,PhD","tristan.ferry@chu-lyon.fr",[33],{"facility":5,"status":34,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Lyon","69004","France","FR",{"type":40,"coordinates":41},"Point",[42,43],4.84789,45.74906,{"lat":43,"lon":42},[46],{"name":47,"role":26,"phone":27,"phoneExt":10,"email":48},"Eugenie Mabrut, CRA","eugenie.mabrut@chu-lyon.fr",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100412442","phage-safety-cohort-study-100412442",false,"NCT04650607","Phage Safety Cohort Study","PHA-SA-CO","Inclusion Criteria:\n\n* Patient 18 years of age or older with a serious infection treated at CRIOAc Lyon by phage therapy\n* Patient who did not object to participating in the study\n* Patients ayant un poids minimum de 46kg\n\nExclusion Criteria:\n\n* Patients under guardianship\u002Fcuratorship\n* Patients deprived of liberty\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":61,"type":62},100,"ESTIMATED","OBSERVATIONAL","This cohort study aims to describe the adverse events related to the use of bacteriophages to treat serious infections, data from the literature being almost non-existent on this subject.",[66,67],"Prosthetic Joint Infection","Severe Infection",[69,70,71,72],"phage","adverse event","severe infection","compassionate treatment","2023-04-12",{"date":75,"type":76},"2023-04-13","ACTUAL",{"date":78,"type":76},"2022-05-09",{"date":80,"type":62},"2028-05-09",{"name":5,"class":6},1]